Study: Cigarette filters are an underestimated source of microplastic pollution
Peer-Reviewed Publication
Updates every hour. Last Updated: 8-Jun-2026 05:16 ET (8-Jun-2026 09:16 GMT/UTC)
A new University at Buffalo study examines what happens to discarded cigarette butts when released into the environment. Findings showing that one cigarette filter can release up to two dozen microfibers almost immediately upon contacting water. More than 100 additional microfibers may break free of the filter within 10 days depending on how the water is moving.
This quick release of cellulose acetate fibers – what most cigarette filters are made of – had not been precisely measured before. This builds upon the evidence that cigarette butts –the most littered item worldwide – are a direct and underestimated source of microplastic pollution.
Researchers have mapped the cellular diversity of the eye’s fluid drainage tissue, identifying a cell subtype that shows early signs of dysfunction in a genetic mouse model of glaucoma. Their study, published today in eLife as the final Version of Record after appearing previously as a Reviewed Preprint, provides what the editors say are fundamental findings, highlighting vitamin B3 treatment as a potential therapeutic strategy for preventing or slowing the development of glaucoma.
Negative memory bias, the tendency to remember negative experiences more easily than positive ones, can fuel cycles of anxiety and depression. In a recent study, researchers from the University of Toyama identified Cognitive bias modification for memory bias (CBM-M) as a potential, accessible intervention for people at risk. Using a randomized controlled trial and brain imaging techniques, the study shows that CBM-M can reduce psychological and biological stress and alter brain circuits linked to emotional memory.
Recently, a research team led by Professor Zhang Jiachao from the College of Food Science and Engineering, Hainan University, published a new study in Science Bulletin entitled “Calenduloside E produced by Bifidobacterium animalis B960 increases glibenclamide efficacy and alleviates drug-induced adverse effects in a type 2 diabetes model.” This study directly addresses the long-standing challenge of the “microbial drug black hole” in the pharmacotherapy of metabolic diseases. The team successfully identified a tropical probiotic strain with dual “efficacy-enhancing and toxicity-reducing” properties, Bifidobacterium animalis subsp. lactis B960 (B960). For the first time, the researchers systematically elucidated the molecular mechanism by which this strain produces the functional metabolite Calenduloside E to synergistically enhance the therapeutic efficacy of glibenclamide while mitigating its adverse effects. Importantly, these findings were further validated using a human-derived gut–liver interconnected organ-on-a-chip platform that recapitulates key aspects of the human physiological microenvironment in vitro. Overall, this work provides an innovative strategy for the development of probiotic-based adjuvant therapies for the treatment of type 2 diabetes.
The mini review brings together emerging evidence showing that glial cells actively influence disease progression and treatment response. Once considered simple support cells, glia are now recognized as dynamic regulators of brain health, playing both protective and harmful roles in neural function.